In view of the approval of capivasertib for the treatment of adult patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, QuIP is conducting the proficiency test “PIK3CA/AKT1/PTEN Mutation Analysis (MolPath)” 2025. Capivasertib is administered in combination with fulvestrant for patients following recurrence or progression on or after an endocrine-based therapy.
- PIK3CA/AKT1/PTEN Mutation Analysis (MolPath): 925,-€
- Testing period: 12.05.2025 until 02.06.2025
Please note the short registration period until 14.03.2025 as well as the proficiency test instructions. You can register for the proficiency test here.
